• Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group 

      Gregersen, Henrik; Peceliunas, Valdas; Remes, Kari; Schjesvold, Fredrik Hellem; Abildgaard, Niels; Nahi, Hareth; Andersen, Niels Frost; Vangsted, Annette Juul; Klausen, Tobias Wirenfeldt; Helleberg, Carsten; Carlson, Kristina; Frølund, Ulf Christian; Axelsson, Per; Stromberg, Olga; Blimark, Cecilie Hveding; Crafoord, Jacob; Tsykunova, Galina; Eshoj, Henrik Rode; Waage, Anders; Hansson, Markus; Gulbrandsen, Nina (Peer reviewed; Journal article, 2021)
      Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and ...
    • Highly expressed genes in multiple myeloma cells – what can they tell us about the disease? 

      Børset, Magne; Elsaadi, Samah; Vandsemb, Esten Nymoen; Hess, Eli Svorkdal; Steiro, Ida Johnsen; Cócera Fernández, Miguel; Sponaas, Anne-Marit; Abdollahi, Pegah (Peer reviewed; Journal article, 2022)
      Cancer cells can convert proto-oncoproteins into oncoproteins by increasing the expression of genes that are oncogenic when expressed at high levels. Such genes can promote oncogenesis without being mutated. To find ...
    • Patterns of previous and secondary malignancies in patients with multiple myeloma 

      Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2021)
      Objectives: In contrast to secondary primary malignancies (SPM) following multiple myeloma (MM), less is known about previous malignancies. We therefore conducted a population-based study to assess the patterns of previous ...